Product Description
Eribulin injection is used to treat metastatic (cancer that has already spread to other parts of the body) breast cancer in patients who have already received other types of cancer medicines. Eribulin injection is also used to treat metastatic liposarcoma or liposarcoma that cannot be removed with surgery in patients who have received other types of cancer medicines.
Mechanisms of Action: Tubulin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, China, France, Germany, Israel, Italy, Japan, Korea, Spain, United Kingdom, United States
Active Clinical Trial Count: 26
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Breast Cancer|Male Breast Cancer
Phase 2: Alopecia|Brain Cancer|Carcinosarcoma|Epithelioid Hemangioendothelioma|Esophageal Cancer|Gastrointestinal Cancer|Hemangiopericytoma|Hemangiosarcoma|Histiocytoma, Malignant Fibrous|Leiomyosarcoma|Liposarcoma|Mixed Tumor, Mullerian|Oncology Solid Tumor Unspecified|Small Cell Lung Cancer|Solitary Fibrous Tumors|Triple Negative Breast Cancer
Phase 1: Adenoid Cystic Carcinoma|Esophageal Cyst|Lymphoma|Peritoneal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT06957431 | P1 |
Recruiting |
Liposarcoma|Leiomyosarcoma |
2028-11-30 |
50% |
2025-10-28 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
| STUDY00017190 | P1 |
Active, not recruiting |
Liposarcoma|Peritoneal Cancer |
2023-02-14 |
12% |
2023-09-15 |
|
| BOLD 113 | P1 |
Active, not recruiting |
Lymphoma |
2020-03-02 |
2025-06-29 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
| E7389-J081-114 | P1 |
Active, not recruiting |
Small Cell Lung Cancer|Gastrointestinal Cancer|Adenoid Cystic Carcinoma|Esophageal Cyst|Esophageal Cancer|Breast Cancer |
2018-07-19 |
50% |
2024-03-02 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| The ARETHA Study | P2 |
Recruiting |
Triple Negative Breast Cancer |
2027-10-01 |
12% |
2022-10-07 |
Primary Endpoints |
| NCT04986579 | P2 |
Recruiting |
Breast Cancer|Alopecia |
2026-06-01 |
75% |
2024-06-28 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| SABINA | P2 |
Recruiting |
Breast Cancer |
2026-04-01 |
2% |
2025-09-23 |
Primary Completion Date|Primary Endpoints|Treatments |
| E7389-J081-120 | P2 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2026-03-31 |
12% |
2024-12-11 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| EPOCH | P2 |
Recruiting |
Mixed Tumor, Mullerian|Carcinosarcoma |
2025-03-01 |
12% |
2025-02-05 |
|
| ERASING | P2 |
Completed |
Solitary Fibrous Tumors|Hemangiopericytoma |
2024-09-18 |
42% |
2024-09-21 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| NCT03899805 | P2 |
Completed |
Liposarcoma|Histiocytoma, Malignant Fibrous|Leiomyosarcoma |
2024-07-16 |
12% |
2025-08-29 |
Primary Endpoints |
| NCT03331250 | P2 |
Active, not recruiting |
Epithelioid Hemangioendothelioma|Hemangiosarcoma |
2023-07-21 |
12% |
2024-11-09 |
Primary Completion Date|Primary Endpoints|Treatments |
| DETECT - IV | P2 |
Completed |
Triple Negative Breast Cancer|Male Breast Cancer |
2023-06-17 |
2022-03-13 |
Treatments |
|
| ERIBRAIN | P2 |
Completed |
Breast Cancer|Brain Cancer |
2023-03-11 |
50% |
2025-05-06 |
Treatments|Trial Status |
| Morpheus-panBC | P2 |
Recruiting |
Breast Cancer |
2028-05-03 |
12% |
2024-08-28 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date |
| 02AB21-TucErBit | P2 |
Recruiting |
Breast Cancer |
2027-06-01 |
2% |
2025-01-14 |
Primary Endpoints |
| MEDOPP437 | P2 |
Recruiting |
Triple Negative Breast Cancer |
2026-12-30 |
2025-05-02 |
Treatments |
|
| MEN1611 IN METAPLASIC BREAST CANCER | P2 |
Active, not recruiting |
Breast Cancer |
2026-04-20 |
2% |
||
| 2020-004909-32 | P2 |
Completed |
Breast Cancer |
2024-10-01 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
| Second line ERIbulin followed by CApecitabine or the reverse sequence in HER2-negative Metastatic Br | P2 |
Completed |
Breast Cancer |
2024-08-30 |
2025-05-06 |
||
| JapicCTI-194960 | P2 |
Active |
Gastrointestinal Cancer|Small Cell Lung Cancer|Esophageal Cancer |
2022-08-31 |
|||
| KELLY study (KEytruda and EribuLin in Luminal breast cancer) | P2 |
Active, not recruiting |
Breast Cancer |
2019-08-31 |
2022-03-13 |
Treatments |
|
| ROSETTA Breast-01 | P3 |
Not yet recruiting |
Breast Cancer |
2029-12-01 |
2025-09-16 |
Primary Endpoints|Treatments |
|
| EMERALD | P3 |
Completed |
Breast Cancer |
2024-12-31 |
2025-09-30 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
| CTR20130252 | P3 |
Active, not recruiting |
Male Breast Cancer |
2018-09-30 |
2025-04-29 |
Patient Enrollment|Treatments |